Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has registered a Phase III study on chinadrugtrials.org.cn to evaluate the efficacy of BL-B01D1 combined with osimertinib versus osimertinib alone as a first-line therapy for EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC). The study, led by Professor Zhou Caicun from East Hospital, aims to enroll 696 patients.
Study Details
The trial will compare the combination therapy of BL-B01D1 and osimertinib with osimertinib monotherapy. BL-B01D1 is an antibody drug conjugate (ADC) targeting EGFR and HER3, developed in-house by Biokin.
Additional Information
BL-M08D1, another in-house ADC targeting EGFR and HER3, is currently under investigation in multiple clinical studies in the U.S. and China. These studies cover various cancer types, including NSCLC, small cell lung cancer, breast cancer, esophageal squamous cell carcinoma, and nasopharyngeal carcinoma. The drug is also being explored in combination with PD-(L)1 inhibitors and tyrosine kinase inhibitors (TKIs).-Fineline Info & Tech
